In another study, synergistic anti-tumor effects of artesunate and sorafenib were detected against hepatocellular carcinoma cells (PLC/PRF/5, HuH7, HepG2, Hep3B and HCCLM3) through targeting the ERK pathway and STAT3 [121]. The gene discussed is STAT3; the disease is neoplasm.